Welichem Biotech, Inc.
| TSX Venture Exchange: WBI
Welichem Biotech, Inc. is a drug discovery and early stage drug development company focusing on novel therapeutics for autoimmune/inflammatory diseases and cancers. The company's focus has been on research and development of its novel anti-inflammatory drug candidate, WBI-1001 and its derivatives, and its unique anticancer drug candidate, WBI-2100 and its derivatives. Welichem Biotech was founded on November 1, 2004 and is headquartered in Burnaby, Canada.